Ery-Tab (erythromycin base)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Erythromycin is a macrolide antibiotic.
USES: Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic.
It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu).
Using any antibiotic when it is not needed can cause it to not work for future infections.
Generic name: erythromycin base
Pronunciation: (e-RITH-roe-MYE-sin base)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Ery-Tab
Indications
The following indications are listed for Ery-Tab:
- Acute Bacterial Otitis Media
- Acute Bacterial Sinusitis
- Acute Streptococcal Pyogenes Bacterial Sinusitis
- Acute Streptococcus Pneumoniae Bacterial Sinusitis
- Bacterial Pneumonia
- Chlamydia Cervicitis
- Chlamydia Trachomatis Urethritis
- Chlamydial Conjunctivitis
- Chlamydial Pneumonia
- Diphtheria
- Diphtheria Carrier State
- Erythrasma
- Legionnaires' Disease
- Listeriosis
- Mycoplasmal Pneumonia
- Neonatal Pneumonia
- Nongonococcal Urethritis
- Pertussis
- Pharyngitis Due To Streptococcus Pyogenes
- Pneumococcal Acute Otitis Media
- Pneumococcal Pharyngitis
- Pneumococcal Pneumonia
- Post-Exposure Diphtheria Prevention
- Preoperative Bowel Preparation
- Rectal Chlamydia Trachomatis Infection
- Rheumatic Fever Prevention
- Skin And Skin Structure Infection
- Skin And Skin Structure Streptococcus Pyogenes Infection
- Staphylococcus Aureus Skin And Skin Structure Infection
- Streptococcus Acute Otitis Media
- Syphilis
Also known as: Acute Otitis Media Due To Diplococcus Pneumoniae, Acute Otitis Media Due To Fraenkel's Pneumococcus, Acute Otitis Media Due To Pneumococcus, Acute Otitis Media Due To Pneumonococcus, Acute Otitis Media Due To Streptococcus Pneumoniae, Acute Otitis Media Due To Streptococcus Species, Acute Sinusitis Due To Diplococcus Pneumoniae, Acute Sinusitis Due To Fraenkel's Pneumococcus, Acute Sinusitis Due To Fraenkel's Pneumonococcus, Acute Sinusitis Due To Group A Beta-Hemolytic Strep, Acute Sinusitis Due To Pneumococcus, Acute Sinusitis Due To Streptococcus Epidemicus, Acute Sinusitis Due To Streptococcus Pneumoniae, Acute Sinusitis Due To Streptococcus Pyogenes, Acute Sinusitis From Fraenkel-Weichselbaum Pneumococcus, Bacterial Otitis Media, Cervicitis Due To Chlamydia Trachomatis, Diphtheria Carrier, Diphtheritis, Diphtheritis Prophylaxis, Post-Exposure, Eaton Agent Pneumonia, Epidemic Sore Throat, Fraenkel-Weichselbaum Pneumococcus Acute Otitis Media, Infection Due To Listeria Monocytogenes, Infection Of Skin And/Or Subcutaneous Tissue, Infection Of The Lungs Due To Chlamydia, Legionellosis, Ngu Due To Chlamydia Trachomatis, Nongonococcal Urethritis Due To Chlamydia Trachomatis, Pharyngitis Due To Group A Beta-Hemolytic Streptococci, Pharyngitis Due To Streptococcus Epidemicus, Pharyngitis Due To Streptococcus Pneumoniae, Pneumonia Due To Streptococcus Pneumoniae, Post-Exposure Diphtheria Prophylaxis, Primary Atypical Pneumonia, Rectal Infection Due To Chlamydia Trachomatis, Rheumatic Fever Prophylaxis, Septic Sore Throat, Skin & Skin Soft Tissue Streptococcus Pyogenes Infection, Skin And Skin Soft Tissue Staphylococcus Aureus Infection, Skin And Soft Tissue Skin Infection, Streptococcal Pharyngitis, Syriac Ulcer, Syriac Ulcer Prophylaxis, Post-Exposure, Trachelitis Due To Chlamydia Trachomatis, Urethritis Due To Chlamydia Trachomatis.
Dosing
The usual adult oral dosage of erythromycin is 250 mg every 6 hours, 333 mg every 8 hours, or 500 mg every 12 hours. In severe infections, dosage may be increased up to 4 g daily; however, a twice-daily dosing schedule is not recommended when dosages exceeding 1 g daily are administered.
The usual oral erythromycin dosage in children is 30-50 mg/kg daily given in 2-4 equally divided doses. For more severe infections, this dosage may be doubled but should not exceed 4 g daily. A twice-daily dosing schedule is not recommended when dosages exceeding 1 g daily are administered.
Erythromycin base is administered orally. The manufacturers of erythromycin delayed-release tablets state that these tablets are well absorbed and may be given without regard to meals. The manufacturers of erythromycin delayed-release capsules (containing enteric-coated pellets) and erythromycin film-coated tablets state that optimal absorption generally occurs when these preparations are administered in the fasting state (at least 30 minutes and, preferably, 2 hours before or after meals). Delayed-release tablets containing enteric-coated particles are well absorbed in most patients and may be given without regard to meals, but the manufacturer states that optimal absorption still occurs if such tablets are administered in the fasting state (at least 30 minutes and, preferably, 2 hours before meals).
The commercially available delayed-release capsules containing enteric-coated pellets of erythromycin (ERYC(R)) may be swallowed intact or the entire contents of a capsule(s) may be sprinkled on a small amount of applesauce immediately prior to administration; subdividing the contents of a capsule is not recommended. The enteric-coated pellets contained in the capsules should not be chewed or crushed. If the capsule contents are administered by sprinkling on applesauce, the patient should drink some water after swallowing the applesauce to ensure that the pellets are swallowed. If the pellets are accidentally spilled, the dose preparation should be started over with a new capsule.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.